Fundraising Fox

Molecular Assemblies

San Diego, US · Delaware corporation · 8 known investors

molecularassemblies.com ↗

Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification. The company serves researchers and developers in therapeutics, vaccines, immunotherapy, agriculture, and nanotechnology.

BiotechDeep TechNew Materials

Founders & leadership

JW
J. William Efcavitch, Ph.D.Treasurer and Chief Scientific Officer
MJ
Michael J. KamdarPresident, Chief Executive Officer and Secretary

Board

DH
David HwangBoard director
LS
Larry StambaughChairman of the Board of Directors
JN
John NicolsBoard director
TP
Todd PetersonBoard director
HB
Helge BastianBoard director

Investors · 8

11.2 CapitalLas Vegas · $500K – $3M
DCVC (Data Collective)Palo Alto · $5M – $25M
iSelect FundSt. Louis · $250K – $2M
AlexandriareportedPasadena
Argonautic VenturesreportedNew York · $5M
Casdin CapitalreportedNew York
Keshif VenturesreportedSan Diego
LYFE CapitalreportedMenlo Park

Reported raises · per SEC filings

Form D private placements

$46.6M disclosed across 3 of 4 rounds · 2016–2021

▶$25.9MraisedSep 2022 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Helge BastianDirector
  • John NicolsDirector
  • J. William Efcavitch, Ph.D.Executive Officer, Director
  • Michael J. KamdarExecutive Officer, Director
  • Todd PetersonDirector
  • Jeffrey Sampson, Ph.D.Director
  • Larry StambaughDirector
Offering amount
$40M
Amount sold
$25.9M
First sale
Sep 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14.1MraisedSep 2021 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael J. KamdarExecutive Officer, Director
  • David HwangDirector
  • Larry StambaughDirector
  • John NicolsDirector
  • Todd PetersonDirector
  • Helge BastianDirector
  • J. William Efcavitch, Ph.D.Executive Officer, Director
Offering amount
$16.3M
Amount sold
$14.1M
First sale
Sep 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.2MofferedJul 2020 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael J. KamdarDirector, Executive Officer
  • David HwangDirector
  • Larry StambaughDirector
  • J. William Efcavitch, Ph.D.Director, Executive Officer
  • John NicolsDirector
  • Todd PetersonDirector
  • Helge BastianDirector
Offering amount
$4.2M
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.5MraisedJul 2018 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Larry StambaughDirector
  • J. William Efcavitch, Ph.D.Director, Executive Officer
  • Joe H. SmithDirector
  • Michael J. KamdarDirector, Executive Officer
  • Sean FreemanExecutive Officer, Director
Offering amount
$9.8M
Amount sold
$6.5M
First sale
Sep 2016
Incorporated
Corporation, California, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$256.2K
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$189K
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$223K
National Science FoundationPhase I2014$150K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Molecular Assemblies, Inc. Secures $83M to Fuel the Fully Enzymatic DNA Synthesis Revolution | SignalBaseleadsontrees.com · Apr 2025Molecular Assemblies Achieves Key Milestones in DARPA NOW Project for On-Demand DNA Vaccine Manufacturingprnewswire.com · Aug 2024Molecular Assemblies Announces $25.8 Million Series B Financing to Initiate Key Customer Program for Commercial Access to Fully Enzymatic DNA Synthesisprnewswire.com · Mar 2022Molecular Assemblies Announces $12.2 M Series A Financing to Advance Enzymatic DNA Synthesis for Life Sciences and Data Storageprnewswire.com · Oct 2019Molecular Assemblies Raises $12.2M in Series A Financing | Genomewebgenomeweb.com · Oct 2019Molecular Assemblies Raises $2.3 Million in Seed Roundprnewswire.com · Dec 2016

Frequently asked questions

What does Molecular Assemblies do?
Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification. The company serves researchers and developers in therapeutics, vaccines, immunotherapy, agriculture, and nanotechnology.
Who founded Molecular Assemblies?
Molecular Assemblies was founded by J. William Efcavitch, Ph.D..
Who are Molecular Assemblies's investors?
Molecular Assemblies's investors include 11.2 Capital, DCVC (Data Collective), iSelect Fund, Alexandria, Argonautic Ventures, Casdin Capital, Keshif Ventures, LYFE Capital.
How much funding has Molecular Assemblies raised?
Molecular Assemblies has disclosed $46.6M raised across 3 of its 4 known rounds.
Where is Molecular Assemblies headquartered?
Molecular Assemblies is headquartered in San Diego, US.